Innovative Implant Uses Oxygenation to Treat Type 1 Diabetes
A new implant system developed at Cornell University offers a promising approach to treating type 1 diabetes by oxygenating insulin-producing cells, potentially reducing dependence on immunosuppressive drugs and enabling better disease management.
Researchers at Cornell University have developed a groundbreaking implant system designed to treat type 1 diabetes by enhancing oxygen supply to insulin-producing cells. This novel device delivers oxygen directly to densely packed pancreatic cells, allowing them to function effectively without needing immunosuppressive drugs. The system consists of a cylindrical capsule housing transplanted insulin-secreting cells and a compact electrochemical oxygen generator the size of a dime, which can be removed as needed. A nanofibrous membrane protects the cells from immune attacks, while a permeable membrane ensures the transfer of oxygen and nutrients.
The technology builds upon previous implantable devices developed in the lab of Professor Minglin Ma, who has previously achieved success controlling blood sugar in diabetic mice but faced limitations due to oxygen deprivation leading to cell death. By introducing the oxygen generator, the new system maintains an adequate oxygen supply, significantly prolonging the survival and functionality of transplanted cells.
The device has been successfully tested in rat models, demonstrating its potential to support high-density cell transplantation and immune protection. Future steps include testing in pig models and exploring applications for other chronic diseases requiring local delivery of therapeutic molecules.
This approach could revolutionize treatment options for the approximately 2 million people with type 1 diabetes in the U.S., enabling more effective and potentially curative therapies without the risks associated with immune suppression. The implant's ability to provide tighter sugar control could allow patients to manage their condition naturally, with fewer daily interventions.
The system's innovative design emphasizes immune protection, efficient oxygenation, and compatibility with long-term use, paving the way for advanced cell therapies. The research team is also exploring broader applications, including delivering other therapeutic proteins and addressing autoimmune and inflammatory diseases.
Source: https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Advancements in Toe Transfer Surgery Improve Outcomes After Finger Amputation
Emerging evidence suggests that toe transfer surgery outperforms finger replantation in restoring hand function after amputation, offering a promising alternative for patients worldwide.
Innovative Four-Drug Regimen Sets New Standard for Treating Multiple Myeloma
A groundbreaking clinical trial introduces a new four-drug combination that significantly improves outcomes for patients with newly diagnosed multiple myeloma, establishing a fresh standard of care.
Newly Identified Molecule May Clarify Muscle Loss in Type 2 Diabetes
Scientists have discovered a new molecule, TMEM9B-AS1, that may explain muscle loss in people with type 2 diabetes, offering potential for targeted treatments.
Proteoglycan Family Molecules Offer Promising Advances in Breast Cancer Diagnosis and Treatment
Recent research uncovers the potential of proteoglycan molecules as biomarkers and therapeutic targets in breast cancer, promising advances in diagnosis and personalized treatment strategies.